DCGI allows Phase II-III clinical trial of Covaxin on 2 to 18-years-old

The Drugs Controller General of India (DCGI) has accorded permission to conduct the Phase II-III clinical trial of Covaxin in the age group of two to 18-years-old to its manufacturer Bharat Biotech Ltd, Union Health Ministry said on Thursday.

"The trial will be conducted in 525 healthy volunteers," said the Ministry.

In the trial, the Ministry said, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.

In a latest update on the vaccination front, the gap between two doses of the Covishield Covid-19 vaccine can be increased to 12-16 weeks, as per the government panel suggestions.